Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) shares rose 5.8% during mid-day trading on Tuesday . The stock traded as high as $6.92 and last traded at $6.91. Approximately 2,910,226 shares changed hands during mid-day trading, a decline of 13% from the average daily volume of 3,335,453 shares. The stock had previously closed at […]
In a notable insider transaction, Shafique Virani, the Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on November 15, 2023.
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) traded up 12.7% on Wednesday . The stock traded as high as $7.31 and last traded at $7.28. 1,168,220 shares were traded during mid-day trading, a decline of 64% from the average session volume of 3,254,322 shares. The stock had previously closed at $6.46. Wall […]
Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) had its price target cut by Needham & Company LLC from $17.00 to $15.00 in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a buy rating on the stock. Separately, KeyCorp upped their price objective on shares of Recursion Pharmaceuticals from $12.00 to […]
Allspring Global Investments Holdings LLC boosted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 453.7% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 8,073 shares of the company’s stock after purchasing an additional 6,615 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Recursion Pharmaceuticals were worth $60,000 […]